Unichem Laboratories has entered into an agreement to acquire 20% equity stake in the API and intermediate business of Hyderabad based Optimus group. The acquisition value is Rs 120 crore.
The transaction will give the company access to Optimus’ US Food and Drug Administration (USFDA) approved API manufacturing facilities and Optimus will gain from the extensive knowledge base and industry best practices of Unichem.
Unichem Laboratories is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world.